Rachel Simpson, MD
Ophthalmology · Salt Lake City, UTNPI 1982041372
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,015 of the $39,112 with a category attached, or 76.7%. Glaukos Corporation accounts for 77.0% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $19,593, more than ten times the $378 reported in 2019. Among ophthalmology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $521.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$30K
- AbbVie$4K
- Alcon$2K
- Nova Eye, Inc.$1K
- W. L. Gore & Associates, Inc.$840
- NEW World Medical,inc.$379
- plus $793 from 7 others
Across 1 payment — averaging $96,188 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$96K
What the payments were for
- Consulting fees$30,01577%
- Travel & lodging$3,4149%
- Food & beverage$4,40111%
- Entertainment$2431%
- Other$1,0393%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 21 | $30,108 |
| AbbVie(2 entities) | 21 | $3,797 |
| Alcon | 12 | $1,772 |
| Nova Eye, Inc. | 3 | $1,424 |
| W. L. Gore & Associates, Inc. | 1 | $840 |
| NEW World Medical,inc. | 4 | $379 |
| Sight Sciences, Inc. | 6 | $244 |
| Carl Zeiss Meditec, Inc. | 2 | $190 |
| Aerie Pharmaceuticals, Inc. | 1 | $125 |
| Johnson & Johnson Vision Care, Inc. | 1 | $115 |
| Bausch & Lomb Americas Inc. | 1 | $67 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $26 |
| Genentech USA, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$5,477
- iDose$4,625
- XEN GLAUCOMA TREATMENT SYSTEM$2,848
- iStent Trabecular Micro-Bypass Stent System$1,500
- LUMIGAN$1,372
- DURYSTA$1,100
- Voyager DSLT$1,039
- Product in Development$840
- iStent Trabecular Micro-Bypass System Model iS3$721
- Hydrus Microstent$151
- Clareon$142
- OMNI(R) SURGICAL SYSTEM (US)$141
- Rhopressa$125
- Rocklatan$125
- Clareon PanOptix Pro$116
- Tecnis Simplicity$115
- ARTEVO 800$114
- CALLISTO eye$114
- VERACITY SURGICAL$114
How this compares
$39,112 in reported general payments places this provider in the 95th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $10,670 |
| Prednisolone Acetate | 157 | $8,627 |
| LumiganBimatoprost | 18 | $8,615 |
| ZioptanTafluprost/Pf | 13 | $6,156 |
| Ketorolac Tromethamine | 121 | $6,083 |
| Latanoprost | 410 | $6,011 |
| RhopressaNetarsudil Mesylate | 11 | $4,846 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $4,100 |
| Methazolamide | 15 | $4,028 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 212 | $3,615 |
| Brimonidine Tartrate | 115 | $1,817 |
| Timolol Maleate | 165 | $1,746 |
| Fluorometholone | 16 | $1,263 |
| Dorzolamide Hcl | 39 | $1,187 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 38 | $557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $125 | $15,51524 claims |
| AbbVieLumigan | $3,797 | $8,61518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
- Amy LinSalt Lake City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.